Loading clinical trials...
Loading clinical trials...
A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994
Conditions
Interventions
REC-994
Placebo
Locations
15
United States
Xenoscience Inc
Phoenix, Arizona, United States
UCLA
Los Angeles, California, United States
Stanford University
Palo Alto, California, United States
University of Florida
Gainesville, Florida, United States
Lyerly Neurosurgery
Jacksonville, Florida, United States
Cleveland Clinic Florida
Port Saint Lucie, Florida, United States
Start Date
March 17, 2022
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
August 6, 2025
NCT06983132
NCT01764529
NCT05298709
NCT03474614
NCT02946866
Lead Sponsor
Recursion Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions